Study Group: Physicians who Treat Fabry Disease (US)(?)
Council Members in this Study Group: 24
Request a survey with this Study Group
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
FDA has approved lacosamide for add-on therapy of partial onset seizures. It will be marketed by UCB under the brand name Vimpat.
Tecturna or Aliskerin belongs to the new anti hypertensive medication class of direct renin inhibitor. The basic action is to inhibit the renin angiotensin/aldosterone system. As we all have understanding of how ace-i and ARB act in this system at different points and effect the blood pressure,...
Outcomes in patients implanted with the artificial disc compare favorably with single level ACDF after 2 years.
UCB has filed new drug application for regulatory approval for lacosamide through FDA and European Medicines Agency. Primary indication would be the treatment of partial onset seizures (epilepsy)
1. Non- calcium containing binders 2. Good phosphate control 3. Need to keep watching as much longer safety data would help
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Laboratory, Independent
- Academic Institution*
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Director
- Medical Director
- Partner
- Professor
- Research Scientist
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms